Eckert & Ziegler And Full-Life Sign Ac-225 Supply Agreement For Next Generation Radiopharmaceuticals

Eckert & Ziegler and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access to Eckert & Ziegler’s high-purity Actinium-225, a radionuclide for use in developing the next generation of therapeutic radiopharmaceuticals.

Ac-225 has emerged as a highly promising active agent for the treatment of cancer. The radioisotope releases potent alpha particles with high energy and short penetration depths, allowing for precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing impact on surrounding healthy tissue. Based on its potential, clinical and industry experts expect a substantial increase in Ac-225 demand in the coming decade.

“We are delighted to have forged a supply collaboration with Full-Life Technologies, dedicating ourselves to facilitating their journey in clinical development,” said Dr Harald Hasselmann, CEO of Eckert & Ziegler. “Historically, limited Ac-225 supply has impeded progress in both clinical research and commercial applications. With the establishment of our new Ac-225 production facility, we aim to significantly increase access to this important radionuclide, with ramp up at the new facility occurring in the second half of the year.”

“Ac-225 constitutes an essential element within our portfolio of therapeutic compounds, including our lead candidate, 225Ac-FL-020 for the treatment of metastatic castration-resistant prostate cancer,” stated Philippe van Put, General Manager of Full-Life Technologies Europe. “Securing access is imperative for advancing our development and clinical research efforts. Eckert & Ziegler brings great expertise and more than three decades of experience as a radioisotope specialist in support of our ambitious development initiatives.”